Le Lézard

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Pfizer Inc. today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy ...
The Manila Times

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a ...
Targeted Oncology

Sequencing Therapy for HER2-Positive Metastatic Breast Cancer: Emerging Strategies

PATINA supports adding palbociclib to anti-HER2 plus endocrine therapy in HR+/HER2+ disease, and HER2CLIMB-05 validates tucatinib with HP after THP induction. Sequencing trials must address ADC ...

F. Hoffmann-La Roche Ltd: Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

ERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbocicl ...